Is NCT06643221 recruiting in Tucson, AZ?

Yes, NCT06643221 is currently recruiting participants at its Tucson, AZ location. This leukemia clinical trial is actively enrolling qualified participants.

How do I join the leukemia clinical trial in Tucson?

To join this clinical trial in Tucson, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Tucson clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Leukemia Clinical Trial in Tucson, AZ

About This Leukemia Study in Tucson

This study aims to improve the treatment of blood cancer by using exercise to collect healthier immune cells from donors. Allogeneic adoptive cell therapy is a treatment where immune cells from a healthy donor are given to a cancer patient, usually to help prevent or treat cancer relapse after a stem cell transplant. These donor cells can either be directly infused into the patient or grown in a lab to create more specialized immune cells that target and kill cancer. While this therapy has been helpful for many patients, there is a need to make it more effective for a larger group and reduce side effects like graft-versus-host disease (GvHD), where the donor's immune cells attack the patient's healthy tissue. This Early Phase 1 trial will test whether exercise can help produce better immune cells from donors. The investigators will recruit healthy participants for three study groups: 1. Exercise Group: Participants will complete a 20-minute cycling exercise session. The investigators will collect blood samples before, during, and after exercise to study the number and quality of immune cells. The investigators will also use the collected cells to create immune therapies and test their ability to kill cancer cells in the lab and control cancer growth in mice. 2. Exercise and Beta Blocker Group: In this group, participants will complete up to five cycling sessions, with at least a week between each session. Before each session, participants will take either a placebo or a drug (beta blocker) that blocks stress hormones like adrenaline. The investigators will collect blood samples before and during exercise to see how blocking these hormones changes the effect of exercise on immune cells. 3. Isoproterenol Group: Participants in this group will receive a 20-minute infusion of isoproterenol, a drug that mimics the effects of adrenaline. The investigators will collect blood samples before, during, and after the infusion to see if the drug causes similar immune changes to those caused by exercise. Participants can join one, two, or all three groups. This research will help understand whether exercise can improve immune cell therapies for treating blood cancer and reduce the risk of GvHD, making these treatments safer and more effective.

Sponsor: University of Arizona

Who Can Participate

Inclusion Criteria

Participants must:

Be between 21 and 55 years of age.

Be classified as 'low-risk' for graded exercise/stress testing according to ACSM-AHA criteria.

Have no contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast as per FDA guidelines.

Exclusion Criteria

Participants will be excluded if they:

Currently use tobacco products or have quit within the last 6 months.

Have a body mass index (BMI) greater than 34 kg/m² or waist circumference exceeding 102 cm for men and 88 cm for women.

Use any medications known to affect the immune system or regularly take ibuprofen/aspirin, antidepressants, or medications that alter blood pressure or cardiovascular function.

Use of hormone replacement therapy.

Are pregnant or breastfeeding.

Have chronic or debilitating arthritis or have been bedridden in the past three months.

Experienced a common illness (e.g., colds) within the past 6 weeks.

Have central or peripheral nervous disorders, a history of stroke, or major affective disorder.

Are infected with HIV or hepatitis or have any autoimmune disease.

Have known cardiovascular disease or contraindications for the use of isoproterenol, carvedilol, bisoprolol, nadolol, or roflumilast.

Use any prescription medications or have an allergy to beta-blockers.

Have a resting heart rate of less than 50 beats per minute.

Suffer from asthma, emphysema, bronchitis, kidney disease, pheochromocytoma, diabetes, overactive thyroid, or a history of severe anaphylactic reactions.

Are scheduled for surgery. Additionally, participants who meet the inclusion criteria but present with more than one of the following cardiovascular disease (CVD) risk factors will be excluded unless cleared by a cardiologist:

Family History: Myocardial infarction, coronary revascularization, or sudden death before 55 years of age in a father or male first-degree relative, or before 65 years of age in a mother or female first-degree relative.

Hypertension: Systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg.

Dyslipidemia: Total serum cholesterol exceeding 200 mg/dl.

Pre-diabetes: Fasting blood glucose levels between 100 mg/dl and 126 mg/dl.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tucson?

Yes, this clinical trial (NCT06643221) has an active research site in Tucson, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Leukemia Treatment Options in Tucson, AZ

If you're searching for leukemia treatment options in Tucson, AZ, this clinical trial (NCT06643221) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tucson research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all leukemia clinical trials near you to find additional studies recruiting in your area.

Leukemia Clinical Trial in Tucson, AZ

Expert Care in Tucson

IRB Approved

No-Cost Care

Apply for This Tucson Location

Why Participate?

Simple Process